A phase I study of a TIM-3 mAb (LY3321367) as a monotherapy or in combination with an anti-PD-L1 agent demonstrated no dose-limiting toxicities; however, minimal anti-tumor activity was observed, especially in tumors refractory to anti-PD-1/PD-L1 agents [168]. The gene discussed is CD274; the disease is neoplasm.